If AngeLink has a guardian angel, she may well be Dr. Sujuan Ba, Ph.D., who was recently featured as One of the 20 Most Inspiring Women Leaders of 2022 by The Women Leaders Magazine. “Sujuan believed in my vision for…
The AIM-HI Accelerator Fund is honored to be nominated for the 2022 Prix Galien USA Incubators, Accelerators and Equity Award. The newest Prix Galien Award category, “Incubators, Accelerators and Equity,” acknowledges the role played by organizations in guiding the next…
We're excited that Dr. Sujuan Ba, AIM-HI CEO & Co-Founder, is featured as one of the "20 Most Inspiring Women Leaders 2022" by THE WOMEN LEADERS Magazine. Read about her illustrious career leading three successful non-profits in the field of cancer…
Recently, Sujuan Ba, Ph.D., CEO & Co-Founder of the AIM-HI Accelerator Fund, was featured in the series Profiles in Success as a Scientist Trailblazing the Transformation. In the interview, Dr. Ba highlights her path from determined teen to research and eventually nonprofit leadership.…
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome 5 Questions with…
The AIM-HI Accelerator Fund, a spin-off of the National Foundation for Cancer Research, aims to award $1 million to a female-led startup focused on meeting unmet needs across the oncology landscape. The organization is currently accepting applications for its 2021…
We are doing a randomized multi-center international clinical trial with a target population of hepatitis B virus-associated hepatocellular carcinoma. In order to develop PHY906 as a drug, we formed a company called Yiviva, in which Yale is a co-founder… Read…
While a longer recovery course might be expected for someone such as Herbert who faced a more severe illness, there’s also concern for more permanent lung damage, according to Dr. Ronald DePinho, professor and past president of MD Anderson Cancer…
More than 20 years ago, Yale pharmacology professor Yung-Chi Cheng, a leader in drug development for hepatitis B, cancer, and HIV, had a radical idea: What if he could unlock the therapeutic potential of ancient Chinese medicines for treating cancer?…
